検索結果

Data And Statistics | About Senju | SENJU Pharmaceutical

Sales Revenue 2021.3 2022.3* 2023.3* 2024.3* 2025.3* Sales Revenue 40.7 40.8 46.4 48.9 48.9 Operating Profit 5.4 6.9 7.4 7.1 2.4 Ordinary Profit 8.0 9.1 8.7 9.1 2.9 Total Assets 75.8 83.9 88.2 98.4 10

Animal Science | Business Activities | About Senju | SENJU Pharmaceutical

Evolving into a Senses-Enhancing Enterprise with a Consummate Pet-related Product Line Pets are our precious companions. They have the right to enjoy the same comforts we do. Through the development o

Over-The-Counter Medicines | Business Activities | About Senju | SENJU Pharmaceutical

From eye drops to contact lens preparations-Mytear eye solutions head a diverse line of trusted products Building on a reputation for excellence in ophthalmological drugs, Senju Pharmaceutical has cul

General Announcement: September 3, 2024 Senju Pharmaceutical Co., Ltd. Acquisition of Marketing Approval for “ Mytear LUMIFY” Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr.

December 22, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a